CSPC

Pave America Strengthens national presence with additions of Kansas Asphalt and Central States Paving & Concrete

Retrieved on: 
Tuesday, October 10, 2023
Professional Services, Other Construction & Property, Finance, Construction & Property, Urban Planning, Landscape, Partnership, CSPC, Concrete, Partner, Growth, Maintenance, Road, Nightclub, North Central State Airport

Pave America, LLC (“Pave America”) has announced strategic partnerships with two leading industry players: Kansas Asphalt and Central States Paving & Concrete (“CSPC”).

Key Points: 
  • Pave America, LLC (“Pave America”) has announced strategic partnerships with two leading industry players: Kansas Asphalt and Central States Paving & Concrete (“CSPC”).
  • Kansas Asphalt, headquartered in Bucyrus, KS, is a leading provider of asphalt & concrete paving, maintenance & repair, and reconstruction services within Kansas, California, Texas, Ohio, and Iowa.
  • Central States Paving & Concrete is a leading provider of asphalt paving, concrete, sealcoating, striping, patching, and other parking lot maintenance services.
  • The CSPC management team will continue to lead the business going forward as a regional platform within Pave America.

A biotechnology company dedicated to developing BsAb-based therapies in China, YZY Biopharma Officially Listed on Main Board of SEHK

Retrieved on: 
Monday, September 25, 2023
Exercise, YZY, International, Epithelial cell adhesion molecule, CD3, Option, Cancer, Ageing, Stock exchange, CSPC, Immunotherapy, Shijiazhuang Pharma Group, Motherboard, Danna International (Offer Nissim Presents), Trust, Patient, TME, HK, Property management, Pharmaceutical industry

HONG KONG, Sept 25, 2023 - (ACN Newswire) - Wuhan YZY Biopharma Co., Ltd. ("YZY Biopharma" or the "Company", together with its subsidiaries, the "Group", stock code: 2496.HK), is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.

Key Points: 
  • HONG KONG, Sept 25, 2023 - (ACN Newswire) - Wuhan YZY Biopharma Co., Ltd. ("YZY Biopharma" or the "Company", together with its subsidiaries, the "Group", stock code: 2496.HK), is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.
  • As a biotechnology company dedicated to developing BsAb-based therapies, YZY Biopharma's core business model is to in-house discover, develop and commercialize BsAb-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases.
  • The Company has received supports from CSPC Pharmaceutical Group Limited ("CSPC"), a well-known pharmaceutical company in China in 2018.
  • Dr. Zhou Pengfei, the co-founder, chairman, executive director and CEO of YZY Biopharma said, "Today marked a milestone in YZY Biopharma's development.

Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Wednesday, September 13, 2023
Bispecific monoclonal antibody, Malignant pleural effusion, GMP, Antigen, YZY, International, Paracentesis, Epithelial cell adhesion molecule, CD3, CMC, Cancer, Ageing, Haemophilia, Pleural cavity, Stock exchange, CSPC, Peritoneum, Research, Immunotherapy, Shijiazhuang Pharma Group, MPE, Motherboard, Patient, Ophthalmology, SEHK, MA, TME, WIV, Immune system, Epitope, Tumor microenvironment, Ascites, Property management, Vaccine, Fine chemical, Pharmaceutical industry, PRC

The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.

Key Points: 
  • The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.
  • Since its establishment, YZY Biopharma focuses on the development of BsAbs in China.
  • In addition, the Company is also focusing on the development of the TME-targeted BsAbs, including Y101D and Y332.
  • Therefore, the execution of an appropriate CMC development strategy is vital to the success of the overall drug development program.

DAS Solar ranked in BNEF Tier 1 Global PV Manufactures list with N-type modules recognized by the market

Retrieved on: 
Wednesday, August 23, 2023
DAS, BNEF, Face, Workers' Party of Turkey (2017), CSPC, N, PV, TBC, SFOS, Topcon, Renewable energy

BNEF is a leading strategic research provider covering global commodity markets and the disruptive technologies driving the transition to a low-carbon economy.

Key Points: 
  • BNEF is a leading strategic research provider covering global commodity markets and the disruptive technologies driving the transition to a low-carbon economy.
  • As a leading brand in N-type technology, DAS Solar is the first to commercialize a TOPCon production line to gigawatt scale in China.
  • Based on market research and trend analysis, DAS Solar also strategically pursued five groundbreaking technological pathways: TOPCon 4.0, TBC, CSPC, TSiP, and SFOS, comprising these next-generation solar cells.
  • To fulfill the needs of global consumers in a variety of situations, DAS Solar will continue to offer innovative N-type products and technologies in the future.

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

Retrieved on: 
Wednesday, August 16, 2023
PRS, American Society of Clinical Oncology, CSPC, Assistant, Shijiazhuang Pharma Group, HKEX, Patient, Annual general meeting, ADC, Stomach, Society, Safety, Sarah Cannon Research Institute, Medical imaging, Pharmaceutical industry, MSCI

"The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology.

Key Points: 
  • "The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology.
  • CSPC Pharmaceutical Group Limited (HKEX: 01093), is also evaluating SYSA1801 (EO-3021) in an ongoing Phase 1 clinical trial in China (NCT05009966).
  • Preliminary data from CSPC's Phase 1 study were presented at the American Society of Clinical Oncology 2023 Annual Meeting.
  • Elevation Oncology has licensed the exclusive rights to develop and commercialize EO-3021 in all global territories outside Greater China from CSPC.

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Retrieved on: 
Saturday, June 3, 2023
Pancreatic cancer, CT, PRS, MMAE, Neoplasm, DCR, American Society of Clinical Oncology, RECIST, Trae Elston, CSPC, Shijiazhuang Pharma Group, ASCO, ORR, Publication, Patient, Cancer, Annual general meeting, Mab, ADC, Financial toxicity, DAR, Stomach, Society, SD, Pharmaceutical industry, Vaccine, Medical imaging

NEW YORK, June 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.

Key Points: 
  • These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.
  • Elevation Oncology's partner, CSPC, is actively recruiting patients in the Phase 1 clinical trial of SYSA1801 (EO-3021) in China (NCT05009966).
  • "While the study remains ongoing, the responses seen are particularly impressive, especially in the gastric cancer setting in tumors expressing Claudin 18.2.
  • These results are highly informative as Elevation Oncology prepares to initiate a Phase 1 clinical trial of EO-3021 in the US in the second half of 2023."

Fight for Moms' Rights Beyond Mother's Day Weekend

Retrieved on: 
Wednesday, May 17, 2023
CPSC, Pediatrics, Education, Nursing, Parent, Sleep, Pediatrics (journal), American Academy, CSPC, U.S. Consumer Product Safety Commission, Women's rights, History, Government, Mother, Congress, Death, Risk, Infant, Empathy, Health, Caregiver, Safety, Birth control, Residential care

Nursing Support Pillows are safely depended on millions of times a day by mothers and caregivers to aid in breastfeeding their babies.

Key Points: 
  • Nursing Support Pillows are safely depended on millions of times a day by mothers and caregivers to aid in breastfeeding their babies.
  • Despite this, the CPSC is threatening to significantly change or even ban Nursing Pillows.
  • Taking away the rights to choose how to care for, comfort and support children is not the gift any loving mom wants.
  • We must ensure that nursing pillows remain available as the trusted support that moms and caregivers have come to rely on.

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Retrieved on: 
Wednesday, April 26, 2023
Neoplasm, CSPC, Shijiazhuang Pharma Group, ASCO, American Society of Clinical Oncology, Patient, Cancer, Annual general meeting, Society, Medical imaging

The ongoing Phase 1 dose escalation and dose expansion study is evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors and is being conducted in China by Elevation Oncology's partner, CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093).

Key Points: 
  • The ongoing Phase 1 dose escalation and dose expansion study is evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors and is being conducted in China by Elevation Oncology's partner, CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093).
  • Elevation Oncology remains on track to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 in the second half of 2023.
  • "We believe EO-3021 has the potential to address unmet needs for patients with Claudin 18.2-expressing tumors, and we look forward to our partner, CSPC, presenting at ASCO 2023."
  • Title: First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.

HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

Retrieved on: 
Monday, March 6, 2023
Biologics license application, KRX, Patient, Clinical trial, National Medical Products Administration, Injection, Neonatal Fc receptor, Partnership, NMPA, CSPC, GMG, Breakthrough therapy, Observation, Medical imaging, Pharmaceutical industry

KS) announced that its licensed partner Harbour BioMed in Greater China reported positive top-line results from its pivotal Phase 3 clinical trial of batoclimab in generalized myasthenia gravis (gMG) patients.

Key Points: 
  • KS) announced that its licensed partner Harbour BioMed in Greater China reported positive top-line results from its pivotal Phase 3 clinical trial of batoclimab in generalized myasthenia gravis (gMG) patients.
  • This marks the first positive Phase 3 trial outcome for batoclimab worldwide.
  • "We are thrilled with the outstanding results from the study, which were the first Phase 3 data of our anti-FcRn asset batoclimab.
  • Harbour BioMed became HanAll's licensed partner to develop batoclimab in China in September 2017, and entered into a sub-license agreement with CSPC for batoclimab in October 2022.

DelveInsight Evaluates a Robust Prostate Cancer Pipeline as 170+ Influential Pharma Players to Set Foot in the Domain

Retrieved on: 
Thursday, February 16, 2023
ZEN, ADC, Plantar fibromatosis, Safety, Eli Lilly and Company, Acquisition, Merck & Co., Lung, BioNTech, CSPC, Clinical trial, Carcinoma, Prostate cancer, Bristol Myers Squibb, Cancer, John Engen, SCNC, Breast, Pain, Regeneron Pharmaceuticals, GT0918, SE, Lymph, Semen, Advaxis, Growth, Society, AstraZeneca, LAS, ASCO, Janssen Pharmaceuticals, PARP, Urination, Human, Blood, United Kingdom, Therapy, Diagnosis, Common, MRI, Patient, PSMA, Ejaculation, Merck, Nivolumab, Tissue, Biopsy, Free trade areas in Europe, Shijiazhuang Pharma Group, Amgen, Urine, Magnetic resonance imaging, Neoplasm, European, TCE, Dairy, Pharmaceutical industry, Medical imaging, Bayer, Pfizer, Pembrolizumab

LAS VEGAS, Feb. 16, 2023 /PRNewswire/ -- DelveInsight's 'Prostate Cancer Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline prostate cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.

Key Points: 
  • The rise in the number of cases of prostate cancer has led to growing government funding and rising initiatives by public and private organizations to spread awareness about prostate cancer.
  • The emergence of strong pipeline drugs and the presence of novel prostate cancer treatments are the prominent factors that will escalate the growth rate of the prostate cancer therapeutics market.
  • LAS VEGAS, Feb. 16, 2023 /PRNewswire/ -- DelveInsight's ' Prostate Cancer Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline prostate cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.
  • DelveInsight's prostate cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for prostate cancer treatment.